Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Humanitas Hospital, Italy | OTHER |
| IRCCS Ospedale San Raffaele | OTHER |
| Azienda Ulss 2 Marca Trevigiana | OTHER |
Not provided
Not provided
Not provided
Not provided
This is a multicenter, observational prospective and retrospective study which aims are: 1) to compute a scoring model potentially predictive for the diagnosis of fibrosis by CMR in patients with MVP; 2) to identify specific features that may predispose to ≥ mild VAs or SCD in patients with MVP.
Patients with mitral valve prolapse and non-significant mitral regurgitation generally have a good prognosis. A minority of patients with MVP suffers from ventricular arrhythmias. Different demographic, clinical, and electrocardiographic characteristics, as well as morphological and structural features of the MV were described as potential risk factors for ventricular arrhythmias, among which fibrosis of the left ventricular inferolateral wall and posterior papillary muscle as detected by cardiac magnetic resonance.
As cardiac magnetic resonance has some limitations, it is unknown if and which patients with mitral valve prolapse should undergo cardiac magnetic resonance in routine clinical practice, to search for late gadolinium enhancement as a surrogate for myocardial fibrosis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Prospective Cohort | Prospectively enrolled patients will undergo a complete assessment, as clinically indicated, including clinical evaluation, TTE, rest ECG, 24h ECG-monitoring, and CMR. CMR will be performed no more than 6 months apart from other examinations (TTE, rest ECG, 24h ECG-monitoring). | ||
| Retrospective Cohort | Patients will be enrolled retrospectively, in case they have already performed all examinations between 2016 and 2023 |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Prediction of fibrosis by CMR | Clinical, echocardiographic, electrocardiographic, and 24h-ECG monitoring variables will be collected in order to identify potential predictors of fibrosis as detected by cardiac magnetic resonance (CMR). Specifically, the following parameters will be collected.
| June 2026 |
| Measure | Description | Time Frame |
|---|---|---|
| Prediction of ≥ mild Ventricular Arrhythmias and/or Sudden cardiac death in mitral valve | Clinical, echocardiographic, electrocardiographic, and CMR variables will be collected in order to identify potential predictors of ≥mild VAs, as defined by the recently published EHRA consensus document. An accurate description of these variables and the Units of Measure are the same as those reported in the section "Primary Outcome Measures". |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with a diagnosis of mitral valve prolapse by transthoracic echocardiography, independent of mitral regurgitation grade, either affected by Barlow's disease, fibroelastic deficiency, forme frustae of mitral valve prolapse.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gianluca Pontone, MD | Contact | 0258002574 | +39 | gianluca.pontone@cardiologicomonzino.it |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centro Cardiologico Monzino | Recruiting | Milan | Milan | 20131 | Italy |
Not provided
| ID | Term |
|---|---|
| D008945 | Mitral Valve Prolapse |
| ID | Term |
|---|---|
| D016127 | Heart Valve Prolapse |
| D006349 | Heart Valve Diseases |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| June 2026 |
| Clinical data |
| June 2026 |
| Transthoracic echocardiography parameters: |
| June 2026 |
| Rest ECG parameters: |
| June 2026 |
| 24h electrocardiographic monitoring parameters: |
Ventricular arrhythmias (VAs) will be classified as suggested in the recently published EHRA consensus statement:
| June 2026 |
| CMR parameters |
| June 2026 |